BACKGROUND: Antibacterial resistance in Escherichia coli isolates of urinary infections, mainly to fluoroquinolones, is emerging. The aim of our study was to identify the secular trend of resistant E. coli isolates and to characterize the population at risk for colonization or infections with these organisms. PATIENTS AND METHODS: Retrospective analysis of 3,430 E.coli first isolates of urine specimens from patients admitted to the University Hospital Basel in 1997, 2000, 2003, and 2007. RESULTS: Resistance to ciprofloxacin, trimethoprim/sulfamethoxazole, and amoxicillin/clavulanate has increased over the 10-year study period (from 1.8% to 15.9%, 17.4% to 21.3%, and 9.5% to 14.5%, respectively). A detailed analysis of the 2007 data revealed that independent risk factors for ciprofloxacin resistance were age (5.3% < 35 years of age to 21.9% in patients > 75 years; odds ratio [OR] 1.29 per 10 years, 95% confidence interval [CI] 1.15-1.45, p < 0.001) and male gender (OR 1.59, 95% CI 1.05-2.41, p = 0.04). In contrast, nosocomial E. coli isolates were associated with lower odds of ciprofloxacin resistance (OR 0.51, 95% CI 0.28-0.67, p < 0.001). The frequency of resistant isolate rates was not influenced by the clinical significance (i.e., colonization vs urinary tract infection, UTI) or by whether the urine was taken from a urinary catheter. Importantly, the increase in ciprofloxacin resistance paralleled the increase in ciprofloxacin consumption in Switzerland (Pearson's correlation test R(2)= 0.998, p = 0.002). Of note, resistance was less frequent in isolates sent in by general practitioners. However, after adjustment for age and gender, only resistance against amoxicillin/clavulanate was found to be less frequent (OR 0.34, 95% CI 0.16-0.92, p = 0.03). CONCLUSION: Our study reveals that resistance rates have been increasing during the last decade. Published resistance rates may lack information due to important differences regarding age, gender, and probable origin of the isolates. Empirical therapy for UTI should be guided more on individual risk profile and local resistance data than on resistance data banks.
BACKGROUND: Antibacterial resistance in Escherichia coli isolates of urinary infections, mainly to fluoroquinolones, is emerging. The aim of our study was to identify the secular trend of resistant E. coli isolates and to characterize the population at risk for colonization or infections with these organisms. PATIENTS AND METHODS: Retrospective analysis of 3,430 E.coli first isolates of urine specimens from patients admitted to the University Hospital Basel in 1997, 2000, 2003, and 2007. RESULTS: Resistance to ciprofloxacin, trimethoprim/sulfamethoxazole, and amoxicillin/clavulanate has increased over the 10-year study period (from 1.8% to 15.9%, 17.4% to 21.3%, and 9.5% to 14.5%, respectively). A detailed analysis of the 2007 data revealed that independent risk factors for ciprofloxacin resistance were age (5.3% < 35 years of age to 21.9% in patients > 75 years; odds ratio [OR] 1.29 per 10 years, 95% confidence interval [CI] 1.15-1.45, p < 0.001) and male gender (OR 1.59, 95% CI 1.05-2.41, p = 0.04). In contrast, nosocomial E. coli isolates were associated with lower odds of ciprofloxacin resistance (OR 0.51, 95% CI 0.28-0.67, p < 0.001). The frequency of resistant isolate rates was not influenced by the clinical significance (i.e., colonization vs urinary tract infection, UTI) or by whether the urine was taken from a urinary catheter. Importantly, the increase in ciprofloxacin resistance paralleled the increase in ciprofloxacin consumption in Switzerland (Pearson's correlation test R(2)= 0.998, p = 0.002). Of note, resistance was less frequent in isolates sent in by general practitioners. However, after adjustment for age and gender, only resistance against amoxicillin/clavulanate was found to be less frequent (OR 0.34, 95% CI 0.16-0.92, p = 0.03). CONCLUSION: Our study reveals that resistance rates have been increasing during the last decade. Published resistance rates may lack information due to important differences regarding age, gender, and probable origin of the isolates. Empirical therapy for UTI should be guided more on individual risk profile and local resistance data than on resistance data banks.
Authors: Galo Peralta; M Blanca Sánchez; J Carlos Garrido; Inés De Benito; M Eliecer Cano; Luis Martínez-Martínez; M Pía Roiz Journal: J Antimicrob Chemother Date: 2007-07-20 Impact factor: 5.790
Authors: John M Stelling; Karin Travers; Ronald N Jones; Philip J Turner; Thomas F O'Brien; Stuart B Levy Journal: Emerg Infect Dis Date: 2005-06 Impact factor: 6.883
Authors: Miao-Hsia Lin; Clement M Potel; Kamaleddin H M E Tehrani; Albert J R Heck; Nathaniel I Martin; Simone Lemeer Journal: Mol Cell Proteomics Date: 2018-09-19 Impact factor: 5.911
Authors: G Bonkat; G Müller; O Braissant; R Frei; S Tschudin-Suter; M Rieken; S Wyler; T C Gasser; A Bachmann; A F Widmer Journal: World J Urol Date: 2013-01-29 Impact factor: 4.226
Authors: George G Zhanel; Melanie DeCorby; Heather Adam; Michael R Mulvey; Melissa McCracken; Philippe Lagacé-Wiens; Kimberly A Nichol; Aleksandra Wierzbowski; Patricia J Baudry; Franil Tailor; James A Karlowsky; Andrew Walkty; Frank Schweizer; Jack Johnson; Daryl J Hoban Journal: Antimicrob Agents Chemother Date: 2010-08-30 Impact factor: 5.191
Authors: Jesús Rodríguez-Baño; Jesús Oteo; Adriana Ortega; Macarena Villar; M Carmen Conejo; Germán Bou; Maitane Aranzamendi-Zaldumbide; Emilia Cercenado; Mercè Gurguí; Luis Martínez-Martínez; María Merino; Alba Rivera; Antonio Oliver; Irene Weber; Alvaro Pascual; Rosa M Bartolomé; Juan José Gónzalez-López; José Campos Journal: J Clin Microbiol Date: 2013-05-01 Impact factor: 5.948